Zynex Inc. (OTCMKTS:ZYXI)’s stock price traded up 5.1% during mid-day trading on Friday . The company traded as high as $9.10 and last traded at $9.00, 184,200 shares were traded during trading. A decline of 3% from the average session volume of 189,060 shares. The stock had previously closed at $8.56.
A number of equities research analysts have issued reports on the stock. Zacks Investment Research raised shares of Zynex from a “sell” rating to a “hold” rating in a research note on Thursday, June 27th. B. Riley lifted their target price on shares of Zynex from $9.00 to $10.75 and gave the company a “buy” rating in a research note on Friday, August 2nd.
The firm’s 50 day moving average is $9.05 and its 200-day moving average is $7.35. The firm has a market cap of $313.54 million, a price-to-earnings ratio of 40.91 and a beta of 1.05.
In other news, CEO Thomas Sandgaard sold 131,260 shares of the business’s stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $10.58, for a total transaction of $1,388,730.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Large investors have recently bought and sold shares of the company. Vanguard Group Inc. bought a new stake in Zynex in the second quarter valued at about $8,257,000. BlackRock Inc. bought a new stake in Zynex in the second quarter valued at about $6,957,000. Northern Trust Corp bought a new stake in Zynex in the second quarter valued at about $627,000. Acadian Asset Management LLC increased its stake in Zynex by 127.6% in the second quarter. Acadian Asset Management LLC now owns 108,737 shares of the company’s stock valued at $978,000 after acquiring an additional 60,960 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in Zynex in the second quarter valued at about $304,000. Institutional investors own 0.05% of the company’s stock.
About Zynex (OTCMKTS:ZYXI)
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Recommended Story: Front-End Load
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.